Fractalkine/CX3CR1 signaling during neuropathic pain

Frontiers in Cellular Neuroscience

Volumn 8, Issue MAY, 2014, Pages

  Clark, Anna K ^a   Malcangio, Marzia ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Chemokines; Chronic pain; Microglia; Pain; Proteases

Indexed keywords

ADAM10 ENDOPEPTIDASE; ADENOSINE TRIPHOSPHATE; CATHEPSIN; CD11B ANTIGEN; CHEMOKINE RECEPTOR CX3CR1; FRACTALKINE; GREEN FLUORESCENT PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHOLIPASE A2; PHOSPHOLIPASE C; PURINERGIC P2X7 RECEPTOR; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME;

ARTICLE; BRAIN DEPTH STIMULATION; CELL COMMUNICATION; CENTRAL NERVOUS SYSTEM SENSITIZATION; CHRONIC PAIN; GENETIC TRANSCRIPTION; GLIOSIS; HUMAN; MACROPHAGE; MICROGLIA; NERVE CELL PLASTICITY; NEUROPATHIC PAIN; NOCICEPTIVE STIMULATION; NONHUMAN; PERIPHERAL NERVE INJURY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA TRANSLATION; SIGNAL TRANSDUCTION; SPINAL CORD DORSAL HORN;

EID: 84900475018     PISSN: 16625102     EISSN: None     Source Type: Journal    
DOI: 10.3389/fncel.2014.00121     Document Type: Article

References (69)

1. Anand, P., Shenoy, R., Palmer, J. E., Baines, A. J., Lai, R. Y. K., Robertson, J., et al. (2011). Clinical trial of the p38 MAP kinase inhibitor dilmapimod in neuropathic pain following nerve injury. Eur. J. Pain 15, 1040-1048. doi: 10. 1016/j.ejpain.2011.04.005
2. Auffray, C., Fogg, D., Garfa, M., Elain, G., Join-Lambert, O., Kayal, S., et al. (2007). Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. Science 317, 666-670. doi: 10.1126/science.1142883
3. Austin, P. J., and Moalem-Taylor, G. (2010). The neuro-immune balance in neuropathic pain: involvement of inflammatory immune cells, immune-like glial cells and cytokines. J. Neuroimmunol. 229, 26-50. doi: 10.1016/j.jneuroim.2010. 08.013
4. Barclay, J., Clark, A. K., Ganju, P., Gentry, C., Patel, S., Wotherspoon, G., et al. (2007). Role of the cysteine protease cathepsin S in neuropathic hyperalgesia. Pain 130, 225-234. doi: 10.1016/j.pain.2006.11.017
5. Baron, R. (2006). Mechanisms of disease: neuropathic pain-a clinical perspective. Nat. Clin. Pract. Neurol. 2, 95-106. doi: 10.1038/ncpneuro0113
6. Bazan, J. F., Bacon, K. B., Hardiman, G., Wang, W., Soo, K., Rossi, D., et al. (1997). A new class of membrane-bound chemokine with a CX3C motif. Nature 385, 640-644. doi: 10.1038/385640a0
7. Clark, A. K., and Malcangio, M. (2012). Microglial signalling mechanisms: Cathepsin S and Fractalkine. Exp. Neurol. 234, 283-292. doi: 10.1016/j. expneurol.2011.09.012
8. Clark, A. K., Old, E. A., and Malcangio, M. (2013). Neuropathic pain and cytokines: current perspectives. J. Pain Res. 6, 803-814. doi: 10.2147/jpr.s53660
9. Clark, A. K., Staniland, A. A., and Malcangio, M. (2011). Fractalkine/CX3CR1 signalling in chronic pain and inflammation. Curr. Pharm. Biotechnol. 12, 1707-1714. doi: 10.2174/138920111798357465
10. Clark, A. K., Wodarski, R., Guida, F., Sasso, O., and Malcangio, M. (2010). Cathepsin S release from primary cultured microglia is regulated by the P2X7 receptor. Glia 58, 1710-1726. doi: 10.1002/glia.21042
11. Clark, A. K., Yip, P. K., Grist, J., Gentry, C., Staniland, A. A., Marchand, F., et al. (2007). Inhibition of spinal microglial cathepsin S for the reversal of neuropathic pain. Proc. Natl. Acad. Sci. U S A 104, 10655-10660. doi: 10. 1073/pnas.0610811104
12. Clark, A. K., Yip, P. K., and Malcangio, M. (2009). The liberation of fractalkine in the dorsal horn requires microglial cathepsin S. J. Neurosci. 29, 6945-6954. doi: 10.1523/jneurosci.0828-09.2009
13. Combadiere, C., Salzwedel, K., Smith, E. D., Tiffany, H. L., Berger, E. A., and Murphy, P. M. (1998). Identification of CX3CR1. A chemotactic receptor for the human CX3C chemokine fractalkine and a fusion coreceptor for HIV-1. J. Biol. Chem. 273, 23799-23804. doi: 10.1074/jbc.273.37.23799
14. Corcione, A., Ferretti, E., Bertolotto, M., Fais, F., Raffaghello, L., Gregorio, A., et al. (2009). CX3CR1 is expressed by human B lymphocytes and mediates [corrected] CX3CL1 driven chemotaxis of tonsil centrocytes. PLoS One 4:e8485. doi: 10.1371/journal.pone.0008485
15. Coull, J. A., Beggs, S., Boudreau, D., Boivin, D., Tsuda, M., Inoue, K., et al. (2005). BDNF from microglia causes the shift in neuronal anion gradient underlying neuropathic pain. Nature 438, 1017-1021. doi: 10.1038/nature04223
16. Cox, J. J., Reimann, F., Nicholas, A. K., Thornton, G., Roberts, E., Springell, K., et al. (2006). AnSCN9A channelopathy causes congenital inabilitytoexperience pain. Nature 444, 894-898. doi: 10.1038/nature05413
17. Fong, A. M., Robinson, L. A., Steeber, D. A., Tedder, T. F., Yoshie, O., Imai, T., et al. (1998). Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion and activation under physiologic flow. J. Exp. Med. 188, 1413-1419. doi: 10.1084/jem.188.8.1413
18. Fonovic ́, U. P., Jevnikar, Z., and Kos, J. (2013). Cathepsin S generates soluble CX3CL1 (fractalkine) in vascular smooth muscle cells. Biol. Chem. 394, 1349-1352. doi: 10.1515/hsz-2013-0189
19. Foussat, A., Coulomb-L'Hermine, A., Gosling, J., Krzysiek, R., Durand-Gasselin, I., Schall, T., et al. (2000). Fractalkine receptor expression by T lymphocyte subpopulations and in vivo production of fractalkineinhuman. Eur. J. Immunol. 30, 87-97. doi: 10.1002/1521-4141(200001)30:1<87::aid-immu87>3.3.co;2-z
20. Gagnon, M., Bergeron, M. J., Lavertu, G., Castonguay, A., Tripathy, S., Bonin, R. P., et al. (2013). Chloride extrusion enhancers as novel therapeutics for neurological diseases. Nat. Med. 19, 1524-1528. doi: 10.1038/nm.3356
21. Garton, K. J., Gough, P. J., Blobel, C. P., Murphy, G., Greaves, D. R., Dempsey, P. J., et al. (2001). Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J. Biol. Chem. 276, 37993-38001. doi: 10.1074/jbc.M106434200
22. Harrison, J. K., Barber, C. M., and Lynch, K. R. (1994). CDNA cloning of a G-protein-coupled receptor expressed in rat spinal cord and brain related to chemokine receptors. Neurosci. Lett. 169, 85-89. doi: 10.1016/0304-3940(94)90362-x
23. Harrison, J. K., Jiang, Y., Chen, S., Xia, Y., Maciejewski, D., McNamara, R. K., et al. (1998). Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. Proc. Natl. Acad. Sci. U S A 95, 10896-10901. doi: 10.1073/pnas.95.18.10896
24. Harrison, J. K., Jiang, Y., Wees, E. A., Salafranca, M. N., Liang, H. X., Feng, L., et al. (1999). Inflammatory agents regulate in vivo expression of fractalkine in endothelial cells of the rat heart. J. Leukoc. Biol. 66, 937-944.
25. Hu, J. H., Yang, J. P., Liu, L., Li, C. F., Wang, L. N., Ji, F. H., et al. (2012). Involvement of CX3CR1 in bone cancer pain through the activation of microglia p38 MAPK pathway in the spinal cord. Brain Res. 1465, 1-9. doi: 10.1016/j.brainres.2012. 05.020
26. Hughes, P. M., Botham, M. S., Frentzel, S., Mir, A., and Perry, V. H. (2002). Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, during acute and chronic inflammation in the rodent CNS. Glia 37, 314-327. doi: 10.1002/glia. 10037.abs
27. Hundhausen, C., Misztela, D., Berkhout, T. A., Broadway, N., Saftig, P., Reiss, K., et al. (2003). The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood 102, 1186-1195. doi: 10.1182/blood-2002-12-3775
28. Hundhausen, C., Schulte, A., Schulz, B., Andrzejewski, M. G., Schwarz, N., von Hundelshausen, P., et al. (2007). Regulated shedding of transmembrane chemokines by the disintegrin and metalloproteinase 10 facilitates detachment of adherent leukocytes. J. Immunol. 178, 8064-8072. doi: 10.4049/jimmunol. 178.12.8064
29. Imai, T., Hieshima, K., Haskell, C., Baba, M., Nagira, M., Nishimura, M., et al. (1997). Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 91, 521-530. doi: 10.1016/s0092-8674(00)80438-9
30. Irie, O., Kosaka, T., Ehara, T., Yokokawa, F., Kanazawa, T., Hirao, H., et al. (2008). Discovery of orally bioavailable cathepsin S inhibitors for the reversal of neuropathic pain. J. Med. Chem. 51, 5502-5505. doi: 10.1021/jm800839j
31. Ishida, Y., Gao, J. L., and Murphy, P. M. (2008). Chemokine receptor CX3CR1 mediates skin wound healing by promoting macrophage and fibroblast accumulation and function. J. Immunol. 180, 569-579. doi: 10.4049/jimmunol.180. 1.569
32. Jensen, T. S., Gottrup, H., Sindrup, S. H., and Bach, F. W. (2001). The clinical picture of neuropathic pain. Eur. J. Pharmacol. 429, 1-11. doi: 10.1016/S0014-2999(01)01302-4
33. Jones, B. A., Beamer, M., and Ahmed, S. (2010). Fractalkine/CX3CL1: a potential new target for inflammatory diseases. Mol. Interv. 10, 263-270. doi: 10.1124/mi. 10.5.3
34. Jung, S., Aliberti, J., Graemmel, P., Sunshine, M. J., Kreutzberg, G. W., Sher, A., et al. (2000). Analysis of fractalkine receptor CX3CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol. Cell. Biol. 20, 4106-4114. doi: 10.1128/mcb.20.11.4106-4114.2000
35. Karlström, S., Nordvall, G., Sohn, D., Hettman, A., Turek, D., Åhlin, K., et al. (2013). Substituted 7-amino-5-thio-thiazolo[4,5-d]pyrimidines as potent and selective antagonists of the fractalkine receptor (CX3CR1). J. Med. Chem. 56, 3177-3190. doi: 10.1021/jm3012273
36. Kim, K. W., Vallon-Eberhard, A., Zigmond, E., Farache, J., Shezen, E., Shakhar, G., et al. (2011). In vivo structure/function and expression analysis of the CX3C chemokine fractalkine. Blood 118, e156-e167. doi: 10.1182/blood-2011-04-348946
37. Landsman, L., Bar-On, L., Zernecke, A., Kim, K. W., Krauthgamer, R., Shagdarsuren, E., et al. (2009). CX3CR1 is required for monocyte homeostasis and atherogenesis by promoting cell survival. Blood 113, 963-972. doi: 10. 1182/blood-2008-07-170787
38. Lauro, C., Di Angelantonio, S., Cipriani, R., Sobrero, F., Antonilli, L., Brusadin, V., et al. (2008). Activity of adenosine receptors type 1 is required for CX3CL1-mediated neuroprotection and neuromodulation in hippocampal neurons. J. Immunol. 180, 7590-7596. doi: 10.4049/jimmunol.180.11.7590
39. Limatola, C., Lauro, C., Catalano, M., Ciotti, M. T., Bertollini, C., Di Angelantonio, S., et al. (2005). Chemokine CX3CL1 protects rat hippocampal neurons against glutamate-mediated excitotoxicity. J. Neuroimmunol. 166, 19-28. doi: 10.1016/j. jneuroim.2005.03.023
40. Lindia, J. A., McGowan, E., Jochnowitz, N., and Abbadie, C. (2005). Induction of CX3CL1 expression in astrocytes and CX3CR1 in microglia in the spinal cord of a rat model of neuropathic pain. J. Pain 6, 434-438. doi: 10.1016/j.jpain.2005. 02.001
41. Liu, H., and Jiang, D. (2011). Fractalkine/CX3CR1 and atherosclerosis. Clin. Chim. Acta 412, 1180-1186. doi: 10.1016/j.cca.2011.03.036
42. Maciejewski, D., Chen, S., Feng, L., Maki, R., and Bacon, K. B. (1999). Characterization of fractalkine in rat brain cells: migratory and activation signals for CX3CR-1-expressing microglia. J. Immunol. 163, 1628-1635.
43. McMahon, S. B., and Malcangio, M. (2009). Current challenges in glia-pain biology. Neuron 64, 46-54. doi: 10.1016/j.neuron.2009.09.033
44. Meucci, O., Fatatis, A., Simen, A. A., and Miller, R. J. (2000). Expression of CX3CR1 chemokine receptors on neurons and their role in neuronal survival. Proc. Natl. Acad. Sci. U S A 97, 8075-8080. doi: 10.1073/pnas.090017497
45. Milligan, E., Zapata, V., Schoeniger, D., Chacur, M., Green, P., Poole, S., et al. (2005). An initial investigation of spinal mechanisms underlying pain enhancement induced by fractalkine, a neuronally released chemokine. Eur. J. Neurosci. 22, 2775-2782. doi: 10.1111/j.1460-9568.2005.04470.x
46. Milligan, E. D., Zapata, V., Chacur, M., Schoeniger, D., Biedenkapp, J., O'Connor, K. A., et al. (2004). Evidence that exogenous and endogenous fractalkine can induce spinal nociceptive facilitation in rats. Eur. J. Neurosci. 20, 2294-2302. doi: 10.1111/j.1460-9568.2004.03709.x
47. Muehlhoefer, A., Saubermann, L. J., Gu, X., Luedtke-Heckenkamp, K., Xavier, R., Blumberg, R. S., et al. (2000). Fractalkine is an epithelial and endothelial cell-derived chemoattractant for intraepithelial lymphocytes in the small intestinal mucosa. J. Immunol. 164, 3368-3376.
48. Nishimura, M., Kuboi, Y., Muramoto, K., Kawano, T., and Imai, T. (2009). Chemokines as novel therapeutic targets for inflammatory bowel disease. Ann. N Y Acad. Sci. 1173, 350-356. doi: 10.1111/j.1749-6632.2009.04738.x
49. Nishiyori, A., Minami, M., Ohtani, Y., Takami, S., Yamamoto, J., Kawaguchi, N., et al. (1998). Localization of fractalkine and CX3CR1 mRNAs in rat brain: does fractalkine play a role in signaling from neuron to microglia? FEBS Lett. 429, 167-172. doi: 10.1016/s0014-5793(98)00583-3
50. Pan, Y., Lloyd, C., Zhou, H., Dolich, S., Deeds, J., Gonzalo, J. A., et al. (1997). Neu-rotactin, a membrane-anchored chemokine upregulated in brain inflammation. Nature 387, 611-617. doi: 10.1038/42491
51. Papadopoulos, E. J., Fitzhugh, D. J., Tkaczyk, C., Gilfillan, A. M., Sassetti, C., Metcalfe, D. D., et al. (2000). Mast cells migrate, but do not degranulate, in response to fractalkine, a membrane-bound chemokine expressed constitutively in diverse cells of the skin. Eur. J. Immunol. 30, 2355-2361. doi: 10.1002/1521-4141(2000)30:8<2355::aid-immu2355>3.0.co;2-#
52. Papadopoulos, E. J., Sassetti, C., Saeki, H., Yamada, N., Kawamura, T., Fitzhugh, D. J., et al. (1999). Fractalkine, a CX3C chemokine, is expressed by dendritic cells and is up-regulated upon dendritic cell maturation. Eur. J. Immunol. 29, 2551-2559. doi: 10.1002/(sici)1521-4141(199908)29:08<2551::aid-immu2551>3.0. co;2-t
53. Raport, C. J., Schweickart, V. L., Eddy, R. L. Jr., Shows, T. B., and Gray, P. W. (1995). The orphan G-protein-coupled receptor-encoding gene V28 is closely related to genes for chemokine receptors and is expressed in lymphoid and neural tissues. Gene 163, 295-299. doi: 10.1016/0378-1119(95)00336-5
54. Schall, T. J., and Proudfoot, A. E. I. (2011). Overcoming hurdles in developing successful drugs targeting chemokine receptors. Nat. Rev. Immunol. 11, 355-363. doi: 10.1038/nri2972
55. Sheridan, G. K., and Murphy, K. J. (2013). Neuron-glia crosstalk in health and disease: fractalkine and CX3CR1 take centre stage. Open Biol. 3:130181. doi: 10. 1098/rsob.130181
56. Staniland, A. A., Clark, A. K., Wodarski, R., Sasso, O., Maione, F., D'Acquisto, F., et al. (2010). Reduced inflammatory and neuropathic pain and decreased spinal microglial response in fractalkine receptor (CX3CR1) knockout mice. J. Neurochem. 114, 1143-1157. doi: 10.1111/j.1471-4159.2010. 06837.x
57. Stein, C., and Machelska, H. (2011). Modulation of peripheral sensory neurons by the immune system: implications for pain therapy. Pharmacol. Rev. 63, 860-881. doi: 10.1124/pr.110.003145
58. Tarozzo, G., Bortolazzi, S., Crochemore, C., Chen, S. C., Lira, A. S., Abrams, J. S., et al. (2003). Fractalkine protein localization and gene expression in mouse brain. J. Neurosci. Res. 73, 81-88. doi: 10.1002/jnr.10645
59. Tarozzo, G., Campanella, M., Ghiani, M., Bulfone, A., and Beltramo, M. (2002). Expression of fractalkine and its receptor, CX3CR1, in response to ischaemia-reperfusion brain injury in the rat. Eur. J. Neurosci. 15, 1663-1668. doi: 10. 1046/j.1460-9568.2002.02007.x
60. Trang, T., Beggs, S., Wan, X., and Salter, M. W. (2009). P2X4-receptor-mediated synthesis and release of brain-derived neurotrophic factor in microglia is dependent on calcium and p38-mitogen-activated protein kinase activation. J. Neurosci. 29, 3518-3528. doi: 10.1523/JNEUROSCI.5714-08.2009
61. Tsou, C. L., Haskell, C. A., and Charo, I. F. (2001). Tumor necrosis factor-alpha-converting enzyme mediates the inducible cleavage of fractalkine. J. Biol. Chem. 276, 44622-44626. doi: 10.1074/jbc.m107327200
62. Tsuda, M., Shigemoto-Mogami, Y., Koizumi, S., Mizokoshi, A., Kohsaka, S., Salter, M. W., et al. (2003). P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury. Nature 424, 778-783. doi: 10.1038/nature 01786
63. Ulmann, L., Hatcher, J. P., Hughes, J. P., Chaumont, S., Green, P. J., Conquet, F., et al. (2008). Up-regulation of P2X4 receptors in spinal microglia after peripheral nerve injury mediates BDNF release and neuropathic pain. J. Neurosci. 28, 11263-11268. doi: 10.1523/JNEUROSCI.2308-08.2008
64. Verge, G. M., Milligan, E. D., Maier, S. F., Watkins, L. R., Naeve, G. S., and Foster, A. C. (2004). Fractalkine (CX3CL1) and fractalkine receptor (CX3CR1) distribution in spinal cord and dorsal root ganglia under basal and neuropathic pain conditions. Eur. J. Neurosci. 20, 1150-1160. doi: 10.1111/j.1460-9568.2004. 03593.x
65. White, G. E., Tan, T. C. C., John, A. E., Whatling, C., McPheat, W. L., and Greaves, D. R. (2010). Fractalkine has anti-apoptotic and proliferative effects on human vascular smooth muscle cells via epidermal growth factor receptor signalling. Cardiovasc. Res. 85, 825-835. doi: 10.1093/cvr/cvp341
66. Yang, J. L., Xu, B., Li, S. S., Zhang, W. S., Xu, H., Deng, X. M., et al. (2012). Gabapentin reduces CX3CL1 signaling and blocks spinal microglial activation in monoarthritic rats. Mol. Brain 5:18. doi: 10.1186/1756-6606-5-18
67. Yin, Q., Cheng, W., Cheng, M. Y., Fan, S. Z., and Shen, W. (2010). Intrathecal injection of anti-CX3CR1 neutralizing antibody delayed and attenuated pain facilitation in rat tibial bone cancer pain model. Behav. Pharmacol. 21, 595-601. doi: 10.1097/fbp.0b013e32833e7e2a
68. Zhang, X., Wu, Z., Hayashi, Y., Okada, R., and Nakanishi, H. (2014). Peripheral role of cathepsin S in Th1 cell-dependent transition of nerve injury-induced acute pain to a chronic pain state. J. Neurosci. 34, 3013-3022. doi: 10. 1523/JNEUROSCI.3681-13.2014
69. Zhuang, Z. Y., Kawasaki, Y., Tan, P. H., Wen, Y. R., Huang, J., and Ji, R. R. (2007). Role of the CX3CR1/p38 MAPK pathway in spinal microglia for the development of neuropathic pain following nerve injury-induced cleavage of fractalkine. Brain Behav. Immun. 21, 642-651. doi: 10.1016/j.bbi.2006.11.003